Recent studies have demonstrated that PD-1 and PD-L1 overexpression on tumor cells and tumor-infiltrating lymphocytes is correlated with poor outcomes in some patients with cancer, and PD-1/PD-L1 blockade-based immunotherapy has been developed for cancers including solid tumors and hematologic malignancies (13). This evidence concerns the gene CD274 and hematologic disorder.